Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 6/20 | 0.41 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.39 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.38 |
| ▸ | MGLL | Q99685 | 2/20 | 0.37 |
| ▸ | TACR1 | P25103 | 1/20 | 0.36 |
| ▸ | FAAH | O00519 | 1/20 | 0.36 |
| ▸ | POLQ | O75417 | 2/20 | 0.35 |
| ▸ | PHGDH | O43175 | 1/20 | 0.35 |
| ▸ | PLA2G7 | Q13093 | 1/20 | 0.35 |
| ▸ | ABHD6 | Q9BV23 | 1/20 | 0.35 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14677458 | 0.89 | NR1H2 (0.41) | FFAR1NR1H2TACR1POLQPTGDR2 | |
| SCHEMBL14779870 | 0.89 | NR1H2 (0.37) | FFAR1NR1H2MGLLFAAHPOLQ | |
| SCHEMBL14780261 | 0.82 | FFAR1 (0.44) | FFAR1NR1H2 | |
| SCHEMBL14779624 | 0.82 | NR1H2 (0.39) | FFAR1NR1H2TACR1POLQPTGDR2 | |
| SCHEMBL14779622 | 0.82 | NR1H2 (0.39) | FFAR1NR1H2TACR1POLQPTGDR2 | |
| SCHEMBL14778314 | 0.81 | FFAR1 (0.40) | FFAR1GRIN2BNR1H2MGLLFAAH | |
| SCHEMBL14676788 | 0.78 | RORC (0.42) | FFAR1NR1H2 | |
| SCHEMBL14675868 | 0.76 | S1PR1 (0.56) | POLQ | |
| SCHEMBL14676489 | 0.75 | NR1H2 (0.40) | FFAR1NR1H2POLQPTGDR2 | |
| SCHEMBL14779564 | 0.73 | NR1H2 (0.39) | FFAR1NR1H2POLQPTGDR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8772277-B2 | Nitrogen-containing heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-07-08 | — | — | US | disclosed |
| US-20130072467-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2013-03-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130072467-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | ESRRA, ESRRB, ESR2 | FFAR1 538/4885GRIN2B 724/4885NR1H2 16/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.